GILD
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F2583827&ei=kXKaUvDOH7Hr0QGFIA&usg=AFQjCNG824lXLK5Pw3Drdw92MQCihdXaew
Gilead Sciences, Inc. Announces New Collaboration With Mylan Laboratories Ltd And Other Indian Partners
Thursday, 2 Aug 2012 08:30am EDT
Gilead Sciences, Inc. together with Mylan Laboratories Ltd, Ranbaxy Laboratories Ltd and Strides Arcolab Limited, announced that they have entered into agreements to collaborate on promoting access to generic versions of Gilead’s HIV medicine emtricitabine (FTC) in developing countries – including single tablet regimens containing emtricitabine, and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines. Under the new agreements Gilead will provide a technology transfer for the manufacture of emtricitabine, together with funding to assist with investment in process improvements to reduce overall manufacturing costs. 
